NI-1801

N/A

Report date: 2024/07/03 14:49:39

Base Information

Drug NameNI-1801
Drug Alias NameNI-1801
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsMacrophages stimulants +[5] 
TargetsCluster of differentiation 47Mesothelin
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLight Chain Bioscience Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLight Chain Bioscience Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A